search
Back to results

To Evaluate the Efficacy and Safety of Collavant n2 in Individuals With Osteoarthritis of the Knee

Primary Purpose

Osteoarthritis, Knee

Status
Completed
Phase
Not Applicable
Locations
India
Study Type
Interventional
Intervention
Collavant n2 40 mg/day
Glucosamine hydrochloride & Chondroitin sulfate
Microcrystalline cellulose
Sponsored by
Vedic Lifesciences Pvt. Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Osteoarthritis, Knee

Eligibility Criteria

40 Years - 75 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Male and females ≥ 40 to ≤ 75 years suffering from knee joint pain for atleast 3 months before screening.
  2. Body mass index (BMI) ≥ 18.5 and ≤ 29.9 kg/m2
  3. Pain VAS for knee joint pain ≥ 5 and ≤ 7 cm on a 10 cm scale at screening.
  4. Radiographic evidence of grade II/III knee OA based on the Kellgren and Lawrence (KL) radiographic entry criteria for OA - i Grade II: Antero-posterior weight-bearing knee radiograph demonstrates possible joint space narrowing (JSN) with definite osteophyte formation.

    ii Grade III: Antero-posterior weight-bearing knee radiograph demonstrates definite joint space narrowing, multiple osteophyte formations, some sclerosis, and possible deformity of bony ends.

  5. LAI score of ≥ 6 - ≤10 at screening.
  6. Willing to stop the restricted dietary supplements, home-based remedies, and any other form of topical products or medications for knee joint pain relief or any other reason for the entire study duration.

    (Note: only hot and cold fomentation will be allowed, and the participant has to record the daily frequency of fomentation in the diary. The hot/cold fomentation needs to be stopped 48 hours prior to all assessment visits.)

  7. Willing to stop using rescue medication 48 hours prior to all assessment visits.
  8. Using the western toilet at home and/or workplace.
  9. Willingness to participate and comply with the study procedures and required visits.
  10. Ability to understand and sign a written informed consent form, which must be completed before performing study-specific tasks.
  11. Literate and have the ability to complete the study-based questionnaires and tasks.
  12. Female participants of childbearing age must be willing to use the acceptable methods of contraception during the study.

Exclusion Criteria:

1 History of uncontrolled hypertension and/or systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg. 2 Fasting blood glucose (FBG) > 125 mg/dl. 3 Radiographic evidence of Grade I or Grade IV OA based on the KL radiographic criteria for osteoarthritis. 4 Any history of trauma, fractures, or surgery to the index joint. 5 Any planned surgery (diagnostic or therapeutic intervention) to the index joint during the participation in the study. 6 History of use of corticosteroid, disease modifying drugs, glucosamine, chondroitin, and intra-articular treatments including injections of corticosteroid or hyaluronic acid within 6 months of the screening visit and consumption of Omega-3 fatty acids or other joint health supplements within 15 days preceding the screening visit. 7 History of use of gabapentin within 6 weeks and/or methylcobalamin within 2 weeks prior to screening. 8 Known case of deformity of the knee joint or diagnosed on clinical examination during screening. 9 Known case of any joint disorder involving the index joint that includes but is not limited to known rheumatic or inflammatory conditions such as rheumatoid arthritis, osteomyelitis, osteoporosis, severe OA, and bone metastasis. 10 Known cases of gout and/or hyperuricemia (serum uric acid >440 μmol/L). 11 Other pathologic lesions on X-ray of the knee. 12 History of bleeding disorders (e.g., Haemophilia, Sickle cell anaemia, etc.).

13 Participants with abnormal levels of serum thyroid-stimulating hormone (TSH) (< 0.4 to > 4.2 mIU/L). 14 Any history or evidence of allergy to chicken, eggs, or protein products in the past. 15 Alcoholics or known drug dependents. (Alcoholism or heavy alcohol use is interpreted based on alcohol content consumed per day or week. It is defined as more than 4 drinks on any day or more than 14 drinks per week for men. For women, it is defined as more than 3 drinks on any day or more than 7 drinks per week. Standard alcoholic drink is roughly equivalent to 14 grams of pure alcohol, which is found in the following: i 12 ounces (Approx. 350 ml) of regular beer, which is usually about 5% alcohol ii 5 ounces (Approx. 150 ml) of wine, which is typically about 12% alcohol iii 1.5 ounces (Approx. 45 ml) of distilled spirits, which is about 40% alcohol) 16 History of smoking or currently smoking or using any form of smokeless tobacco. 17 Not willing to abstain from the use of NSAIDs (including low dose aspirin 50 mg/day for cardiovascular health). 18 Participation in a study of an investigational product within 90 days prior to the screening.

Sites / Locations

  • Amber Clinic
  • Prme Orthopedic Speciality
  • Diamond Hospital
  • Ayush Nursing Home
  • Life Care Hospital
  • Care n Cure Multispeciality Hospital
  • Sparsh Hospital
  • Lifepoint Multispeciality Hospital
  • Imperial Multispecialty Hospital
  • Gayatri Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Active Comparator

Placebo Comparator

Arm Label

Collavant n2 40 mg/day

Glucosamine hydrochloride & Chondroitin sulfate

Microcrystalline cellulose

Arm Description

2 capsules in the morning before breakfast and 2 capsules at night before going to bed for 180 days

2 capsules in the morning before breakfast and 2 capsules at night before going to bed for 180 days

2 capsules in the morning before breakfast and 2 capsules at night before going to bed for 180 days

Outcomes

Primary Outcome Measures

Western Ontario and McMaster Universities Osteoarthritis Index Pain subscale
Knee joint pain as assessed by the change in the Western Ontario and McMaster Universities Osteoarthritis Index Pain subscale (WOMAC-P) score. the primary efficacy variable for the present study is the total WOMAC index score, the scores for each subscale will be summed up (Pain range: 0-20, Stiffness range: 0-8, and Physical function range: 0-68). Thus, the total WOMAC score will range from 0 - 96. The lowest the score is the good response and highest the score is extreme pain i.e. bad response.

Secondary Outcome Measures

Knee joint pain as assessed by the change in the Western Ontario and McMaster - Pain subscale score.
The first domain, WOMAC-P, comprises 5 questions evaluating the amount of pain due to OA in the index joint experienced by the participant. The WOMAC-P subscale score of 0 indicates 'No pain' and 4 indicates 'Extreme pain'.
Knee joint stiffness as assessed by the change in the WOMAC - Stiffness subscale (WOMAC-S) score.
The domain, WOMAC-S, consists of 2 questions evaluating the amount of stiffness (resistance of the joint to movement characterized by difficulty in moving the joint along with pain and discomfort in the joint) experienced in the index joint. On the Likert scale, 0 indicates 'No stiffness' and 4 indicates 'Extreme stiffness'.
Knee joint function as assessed by the change in the WOMAC - Physical function (WOMAC-PF) score.
The WOMAC-PF consists of 17 questions evaluating the degree of physical difficulty experienced in the index joint due to OA in the third domain. For WOMAC-PF, 0 indicates 'No difficulty' and 4 indicates 'Extreme difficulty'.
Knee joint pain assessed by the change in the Visual Analogue Scale (VAS) score.
Point 0 indicates no pain and 10 indicates worst pain.
Severity of osteoarthritis as assessed by the change in the Lequesne algofunctional index (LAI) score.
Higher scores indicate a worse joint condition and Lowest scores indicate agood joint condition

Full Information

First Posted
July 22, 2022
Last Updated
September 4, 2023
Sponsor
Vedic Lifesciences Pvt. Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT05474586
Brief Title
To Evaluate the Efficacy and Safety of Collavant n2 in Individuals With Osteoarthritis of the Knee
Official Title
A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Collavant n2 in Individuals With Osteoarthritis of the Knee
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Completed
Study Start Date
August 8, 2022 (Actual)
Primary Completion Date
July 4, 2023 (Actual)
Study Completion Date
July 4, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Vedic Lifesciences Pvt. Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
A randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of Collavant n2 in individuals with osteoarthritis of the knee.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis, Knee

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomized, Parallel Group, Placebo Controlled Trial
Masking
ParticipantCare ProviderInvestigator
Masking Description
Sequentially numbered, sealed, opaque envelopes
Allocation
Randomized
Enrollment
236 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Collavant n2 40 mg/day
Arm Type
Experimental
Arm Description
2 capsules in the morning before breakfast and 2 capsules at night before going to bed for 180 days
Arm Title
Glucosamine hydrochloride & Chondroitin sulfate
Arm Type
Active Comparator
Arm Description
2 capsules in the morning before breakfast and 2 capsules at night before going to bed for 180 days
Arm Title
Microcrystalline cellulose
Arm Type
Placebo Comparator
Arm Description
2 capsules in the morning before breakfast and 2 capsules at night before going to bed for 180 days
Intervention Type
Other
Intervention Name(s)
Collavant n2 40 mg/day
Intervention Description
2 capsules in the morning before breakfast and 2 capsules at night before going to bed for 180 days
Intervention Type
Other
Intervention Name(s)
Glucosamine hydrochloride & Chondroitin sulfate
Intervention Description
2 capsules in the morning before breakfast and 2 capsules at night before going to bed for 180 days
Intervention Type
Other
Intervention Name(s)
Microcrystalline cellulose
Intervention Description
2 capsules in the morning before breakfast and 2 capsules at night before going to bed for 180 days
Primary Outcome Measure Information:
Title
Western Ontario and McMaster Universities Osteoarthritis Index Pain subscale
Description
Knee joint pain as assessed by the change in the Western Ontario and McMaster Universities Osteoarthritis Index Pain subscale (WOMAC-P) score. the primary efficacy variable for the present study is the total WOMAC index score, the scores for each subscale will be summed up (Pain range: 0-20, Stiffness range: 0-8, and Physical function range: 0-68). Thus, the total WOMAC score will range from 0 - 96. The lowest the score is the good response and highest the score is extreme pain i.e. bad response.
Time Frame
Day 0, 7, 30, 60, 90, 120, 150, and 180
Secondary Outcome Measure Information:
Title
Knee joint pain as assessed by the change in the Western Ontario and McMaster - Pain subscale score.
Description
The first domain, WOMAC-P, comprises 5 questions evaluating the amount of pain due to OA in the index joint experienced by the participant. The WOMAC-P subscale score of 0 indicates 'No pain' and 4 indicates 'Extreme pain'.
Time Frame
Day 0, 7, 30, 60, 90, 120, 150, and 180
Title
Knee joint stiffness as assessed by the change in the WOMAC - Stiffness subscale (WOMAC-S) score.
Description
The domain, WOMAC-S, consists of 2 questions evaluating the amount of stiffness (resistance of the joint to movement characterized by difficulty in moving the joint along with pain and discomfort in the joint) experienced in the index joint. On the Likert scale, 0 indicates 'No stiffness' and 4 indicates 'Extreme stiffness'.
Time Frame
Day 0, 7, 30, 60, 90, 120, 150, and 180
Title
Knee joint function as assessed by the change in the WOMAC - Physical function (WOMAC-PF) score.
Description
The WOMAC-PF consists of 17 questions evaluating the degree of physical difficulty experienced in the index joint due to OA in the third domain. For WOMAC-PF, 0 indicates 'No difficulty' and 4 indicates 'Extreme difficulty'.
Time Frame
Day 0, 7, 30, 60, 90, 120, 150, and 180
Title
Knee joint pain assessed by the change in the Visual Analogue Scale (VAS) score.
Description
Point 0 indicates no pain and 10 indicates worst pain.
Time Frame
Day 0, 7, 30, 60, 90, 120, 150, and 180
Title
Severity of osteoarthritis as assessed by the change in the Lequesne algofunctional index (LAI) score.
Description
Higher scores indicate a worse joint condition and Lowest scores indicate agood joint condition
Time Frame
Day 0, 7, 30, 60, 90, 120, 150, and 180

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Male and females ≥ 40 to ≤ 75 years suffering from knee joint pain for atleast 3 months before screening. Body mass index (BMI) ≥ 18.5 and ≤ 29.9 kg/m2 Pain VAS for knee joint pain ≥ 5 and ≤ 7 cm on a 10 cm scale at screening. Radiographic evidence of grade II/III knee OA based on the Kellgren and Lawrence (KL) radiographic entry criteria for OA - i Grade II: Antero-posterior weight-bearing knee radiograph demonstrates possible joint space narrowing (JSN) with definite osteophyte formation. ii Grade III: Antero-posterior weight-bearing knee radiograph demonstrates definite joint space narrowing, multiple osteophyte formations, some sclerosis, and possible deformity of bony ends. LAI score of ≥ 6 - ≤10 at screening. Willing to stop the restricted dietary supplements, home-based remedies, and any other form of topical products or medications for knee joint pain relief or any other reason for the entire study duration. (Note: only hot and cold fomentation will be allowed, and the participant has to record the daily frequency of fomentation in the diary. The hot/cold fomentation needs to be stopped 48 hours prior to all assessment visits.) Willing to stop using rescue medication 48 hours prior to all assessment visits. Using the western toilet at home and/or workplace. Willingness to participate and comply with the study procedures and required visits. Ability to understand and sign a written informed consent form, which must be completed before performing study-specific tasks. Literate and have the ability to complete the study-based questionnaires and tasks. Female participants of childbearing age must be willing to use the acceptable methods of contraception during the study. Exclusion Criteria: 1 History of uncontrolled hypertension and/or systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg. 2 Fasting blood glucose (FBG) > 125 mg/dl. 3 Radiographic evidence of Grade I or Grade IV OA based on the KL radiographic criteria for osteoarthritis. 4 Any history of trauma, fractures, or surgery to the index joint. 5 Any planned surgery (diagnostic or therapeutic intervention) to the index joint during the participation in the study. 6 History of use of corticosteroid, disease modifying drugs, glucosamine, chondroitin, and intra-articular treatments including injections of corticosteroid or hyaluronic acid within 6 months of the screening visit and consumption of Omega-3 fatty acids or other joint health supplements within 15 days preceding the screening visit. 7 History of use of gabapentin within 6 weeks and/or methylcobalamin within 2 weeks prior to screening. 8 Known case of deformity of the knee joint or diagnosed on clinical examination during screening. 9 Known case of any joint disorder involving the index joint that includes but is not limited to known rheumatic or inflammatory conditions such as rheumatoid arthritis, osteomyelitis, osteoporosis, severe OA, and bone metastasis. 10 Known cases of gout and/or hyperuricemia (serum uric acid >440 μmol/L). 11 Other pathologic lesions on X-ray of the knee. 12 History of bleeding disorders (e.g., Haemophilia, Sickle cell anaemia, etc.). 13 Participants with abnormal levels of serum thyroid-stimulating hormone (TSH) (< 0.4 to > 4.2 mIU/L). 14 Any history or evidence of allergy to chicken, eggs, or protein products in the past. 15 Alcoholics or known drug dependents. (Alcoholism or heavy alcohol use is interpreted based on alcohol content consumed per day or week. It is defined as more than 4 drinks on any day or more than 14 drinks per week for men. For women, it is defined as more than 3 drinks on any day or more than 7 drinks per week. Standard alcoholic drink is roughly equivalent to 14 grams of pure alcohol, which is found in the following: i 12 ounces (Approx. 350 ml) of regular beer, which is usually about 5% alcohol ii 5 ounces (Approx. 150 ml) of wine, which is typically about 12% alcohol iii 1.5 ounces (Approx. 45 ml) of distilled spirits, which is about 40% alcohol) 16 History of smoking or currently smoking or using any form of smokeless tobacco. 17 Not willing to abstain from the use of NSAIDs (including low dose aspirin 50 mg/day for cardiovascular health). 18 Participation in a study of an investigational product within 90 days prior to the screening.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dr Shalini Srivastava, MD medicine
Organizational Affiliation
Vedic Lifesciences Pvt. Ltd.
Official's Role
Study Director
Facility Information:
Facility Name
Amber Clinic
City
Ahmedabad
State/Province
Gujarat
ZIP/Postal Code
380015
Country
India
Facility Name
Prme Orthopedic Speciality
City
Mumbai
State/Province
Maharashtra
ZIP/Postal Code
400053
Country
India
Facility Name
Diamond Hospital
City
Mumbai
State/Province
Maharashtra
ZIP/Postal Code
400064
Country
India
Facility Name
Ayush Nursing Home
City
Mumbai
State/Province
Maharashtra
ZIP/Postal Code
400067
Country
India
Facility Name
Life Care Hospital
City
Nashik
State/Province
Maharashtra
ZIP/Postal Code
422009
Country
India
Facility Name
Care n Cure Multispeciality Hospital
City
Palghar
State/Province
Maharashtra
ZIP/Postal Code
401209
Country
India
Facility Name
Sparsh Hospital
City
Panvel
State/Province
Maharashtra
ZIP/Postal Code
410206
Country
India
Facility Name
Lifepoint Multispeciality Hospital
City
Pune
State/Province
Maharashtra
ZIP/Postal Code
411057
Country
India
Facility Name
Imperial Multispecialty Hospital
City
Pune
State/Province
Maharashtra
ZIP/Postal Code
411062
Country
India
Facility Name
Gayatri Hospital
City
Vasai
State/Province
Maharashtra
ZIP/Postal Code
401208
Country
India

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

To Evaluate the Efficacy and Safety of Collavant n2 in Individuals With Osteoarthritis of the Knee

We'll reach out to this number within 24 hrs